Free tool
FAERS Monitor: Oxytocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018248 or its brand name (Oxytocin, Oxytocin). Reports on generic versions are filed under their own applications.
Reports
2,568
Serious
2,294
89% of reports
Hospitalization
795
Death reported
145
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy413
- maternal exposure during pregnancy398
- drug ineffective353
- exposure during pregnancy317
- premature baby197
- off label use163
- hypotension160
- premature delivery156
- maternal exposure during delivery112
- low birth weight baby101
- drug exposure during pregnancy99
- postpartum haemorrhage98
- nausea85
- dyspnoea82
- caesarean section77
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 34 |
| 2005 | 22 |
| 2006 | 54 |
| 2007 | 32 |
| 2008 | 51 |
| 2009 | 40 |
| 2010 | 53 |
| 2011 | 51 |
| 2012 | 50 |
| 2013 | 71 |
| 2014 | 87 |
| 2015 | 89 |
| 2016 | 151 |
| 2017 | 124 |
| 2018 | 158 |
| 2019 | 137 |
| 2020 | 193 |
| 2021 | 188 |
| 2022 | 228 |
| 2023 | 266 |
| 2024 | 186 |
| 2025 | 161 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,591 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| maternal exposure during deliverySignal | 112 | 1044.5 | 861.4 | 102,648 |
| postpartum haemorrhageSignal | 98 | 642.7 | 525.2 | 57,634 |
| low birth weight babySignal | 101 | 105.4 | 87.0 | 10,216 |
| premature deliverySignal | 156 | 81.0 | 69.5 | 12,138 |
| caesarean sectionSignal | 77 | 54.5 | 43.7 | 3,966 |
| premature babySignal | 197 | 54.0 | 47.2 | 10,134 |
| exposure during pregnancySignal | 317 | 42.0 | 37.9 | 12,614 |
| foetal exposure during pregnancySignal | 413 | 41.8 | 38.3 | 16,395 |
| maternal exposure during pregnancySignal | 398 | 36.7 | 33.6 | 13,796 |
| drug exposure during pregnancySignal | 99 | 23.9 | 19.7 | 2,148 |
| hypotensionSignal | 160 | 6.5 | 5.6 | 751 |
| drug ineffectiveSignal | 353 | 2.2 | 2.0 | 243 |
| off label use | 163 | 1.5 | 1.3 | 30 |
| dyspnoea | 82 | 1.2 | 1.0 | 2 |
| nausea | 85 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.